64 citations
Counting papers with at most 25 authors, so collaboration author lists do not stand in for the people here.
- Novartis (Switzerland)CH6 papers
- Medical University of ViennaAT3 papers
- Statistics AustriaAT3 papers
- Novartis (China)CN2 papers
- University Hospital MagdeburgDE2 papers
- AstraZeneca (Sweden)SE1 paper
- Berry & Associates (United States)US1 paper
- Berry Consultants, LLC (United States)US1 paper
- Charité - Universitätsmedizin BerlinDE1 paper
- Constellium (United Kingdom)GB1 paper
- Franklin UniversityUS1 paper
- Institute of Neuroimmunology and Multiple SclerosisDE1 paper
Showing 2021Show all
2 papers · 1 filter
stat.ME2021★ 64 cited
On model-based time trend adjustments in platform trials with non-concurrent controls
Marta Bofill Roig, Pavla Krotka, Carl-Fredrik Burman +9
Platform trials can evaluate the efficacy of several treatments compared to a control. The number of treatments is not fixed, as arms may be added or removed as the trial progresse…
stat.AP2021★ 1 cited
Decision rules for identifying combination therapies in open-entry, randomized controlled platform trials
Elias Laurin Meyer, Peter Mesenbrink, Cornelia Dunger-Baldauf +3
Platform trials have become increasingly popular for drug development programs, attracting interest from statisticians, clinicians and regulatory agencies. Many statistical questio…